Details

Autor(en) / Beteiligte

• Baliakas, Panagiotis
• Agathangelidis, Andreas
• Hadzidimitriou, Anastasia
• Sutton, Lesley-Ann
• Minga, Eva
• Tsanousa, Athina
• Scarfò, Lydia
• Davis, Zadie
• Yan, Xiao-Jie
• Shanafelt, Tait
• Plevova, Karla
• Sandberg, Yorick
• Vojdeman, Fie Juhl
• Boudjogra, Myriam
• Tzenou, Tatiana
• Chatzouli, Maria
• Chu, Charles C.
• Veronese, Silvio
• Gardiner, Anne
• Mansouri, Larry
• Smedby, Karin E.
• Pedersen, Lone Bredo
• Moreno, Denis
• Van Lom, Kirsten
• Giudicelli, Véronique
• Francova, Hana Skuhrova
• Nguyen-Khac, Florence
• Panagiotidis, Panagiotis
• Juliusson, Gunnar
• Angelis, Lefteris
• Anagnostopoulos, Achilles
• Lefranc, Marie-Paule
• Facco, Monica
• Trentin, Livio
• Catherwood, Mark
• Montillo, Marco
• Geisler, Christian H.
• Langerak, Anton W.
• Pospisilova, Sarka
• Chiorazzi, Nicholas
• Oscier, David
• Jelinek, Diane F.
• Darzentas, Nikos
• Belessi, Chrysoula
• Davi, Frederic
• Ghia, Paolo
• Rosenquist, Richard
• Stamatopoulos, Kostas

Titel

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations

Ist Teil von

• Blood, 2015-01, Vol.125 (5), p.856-859

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• An unresolved issue in chronic lymphocytic leukemia (CLL) is whether IGHV3-21 gene usage, in general, or the expression of stereotyped B-cell receptor immunoglobulin defining subset #2 (IGHV3-21/IGLV3-21), in particular, determines outcome for IGHV3-21-utilizing cases. We reappraised this issue in 8593 CLL patients of whom 437 (5%) used the IGHV3-21 gene with 254/437 (58%) classified as subset #2. Within subset #2, immunoglobulin heavy variable (IGHV)-mutated cases predominated, whereas non–subset #2/IGHV3-21 was enriched for IGHV-unmutated cases (P = .002). Subset #2 exhibited significantly shorter time-to-first-treatment (TTFT) compared with non–subset #2/IGHV3-21 (22 vs 60 months, P = .001). No such difference was observed between non–subset #2/IGHV3-21 vs the remaining CLL with similar IGHV mutational status. In conclusion, IGHV3-21 CLL should not be axiomatically considered a homogeneous entity with adverse prognosis, given that only subset #2 emerges as uniformly aggressive, contrasting non–subset #2/IGVH3-21 patients whose prognosis depends on IGHV mutational status as the remaining CLL. •CLL stereotyped subset #2 (IGHV3-21/IGLV3-21) is uniformly aggressive independently of somatic hypermutation status.•The prognosis for non–subset #2/IGHV3-21 CLL resembles that of the remaining CLL cases with similar somatic hypermutation status.